High levels of Serum Angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients

Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece.
British Journal of Haematology (Impact Factor: 4.71). 09/2010; 150(5):587-91. DOI: 10.1111/j.1365-2141.2010.08288.x
Source: PubMed


Serum levels of five angiogenic cytokines were evaluated in 82 patients with primary systemic amyloidosis (AL). Angiopoietin-1, vascular endothelial growth factor, basic fibroblast growth factor and angiogenin were higher in AL patients than in controls (n = 35) and newly-diagnosed, symptomatic, myeloma patients (n = 35). Angiopoetin-1/Angiopoetin-2 ratio was lower in AL compared to controls but higher than in myeloma patients. Angiopoetin-2 correlated with cardiac dysfunction indices; however, none of the angiogenic growth factors was prognostically significant. The increased angiogenic cytokine levels observed in AL seem to represent either a toxic effect of amyloid fibrils or light chains, or a compensatory response to organ dysfunction.

Download full-text


Available from: Efstathios Kastritis, Oct 05, 2015
30 Reads
  • Source
    • "Quartarone et al. [38] in their study showed a significant increase in sAng-2 levels with severity of the disease and presented a trend of correlation with β2-microglobulin levels and grade of bone involvement although their sample size was very limited. Kastritis et al. [39] in their study showed significantly higher levels of Ang-2 in MM patients as compared to controls and amyloidosis patients but they have not correlated the data with severity of the disease. Schliemann et al. have also found significantly high Ang-2 expression in the BM of patients with acute myeloid leukemia (AML) [40]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Multiple myeloma (MM) was the first hematological malignancy in which a prognostic relevance of bone marrow (BM) angiogenesis was reported. Microenvironment formed by reactive oxygen species, growth factors and chemokines initiates the process of BM angiogenesis. Among the angiopoietins, angiopoietin-1 is involved in vessel stability, whereas angiopoietin-2 is involved in vessel sprouting. Circulatory levels of angiopoietin-1, angiopoietin-2 and VEGF in 62 MM patients and 50 healthy controls were determined using ELISA. Significant increase in VEGF and angiopoietin-2 level was observed in patients which correlated positively with the severity of the disease, whereas no alteration was observed in angiopoietin-1 levels. Significant elevation in angiopoietin-2 and VEGF levels and their correlation with severity of the disease indicate their utility as potential tumor markers along with β(2)- microglobulin and might also suggest new therapeutic target for anticancer treatment.
    Clinical biochemistry 02/2011; 44(8-9):590-5. DOI:10.1016/j.clinbiochem.2011.01.010 · 2.28 Impact Factor
  • Amyloid: the international journal of experimental and clinical investigation: the official journal of the International Society of Amyloidosis 08/2011; 18(Suppl. 1). DOI:10.3109/13506129.2011.574354039 · 2.01 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The circulating levels of several angiogenic cytokines [angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2), vascular endothelial growth factor (VEGF), angiogenin and basic fibroblast growth factor (bFGF)] were evaluated in 174 consecutive patients with newly diagnosed, symptomatic, multiple myeloma (MM). Circulating levels of Ang-1/Ang-2 were reduced in myeloma patients compared to controls, whereas VEGF and angiogenin levels were increased. Reduced angiopoietin-1/angiopoietin-2 ratio correlated with advanced disease features including international staging system (ISS)-3 stage, renal impairment and extensive bone disease. Based on immunohistochemical results in 20 patients (10 with the higher and 10 with the lower values of circulating angiopoietin-2) we found that angiopoietin-2 is expressed by myeloma cells and correlates with increased microvessel density in subsets of patients. Furthermore, Ang-1/Ang-2 ratio correlated with survival. Patients with circulating Ang-1/Ang-2 below or equal to the median value (6.03) had a median survival of 26.3 months compared to 53 months of all others (p = 0.002). Interestingly, this was mainly observed in patients who received first-line therapy with novel agent-based regimens (65% of our patients). Furthermore, a subset of ISS-3 patients with serum Ang-1/Ang-2 above the median value had favourable prognosis (median survival: 45 months versus 17 months of all others; p = 0.0001). The multivariate analysis revealed that low Ang-1/Ang-2 ratio could independently predict for inferior survival in our cohort of patients (relative risk (RR) 2.07, 95% CI 1.50-2.42; p < 0.001). These results highlight the role of angiopoietins pathway in the biology of MM and reveal novel targets for the development of antimyeloma agents.
    International Journal of Cancer 02/2012; 130(3):735-42. DOI:10.1002/ijc.26062 · 5.09 Impact Factor
Show more